Structure Therapeutics Inc. Sponsored ADR $GPCR is BVF Inc. IL’s 4th Largest Position

BVF Inc. IL lifted its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 8.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,479,022 shares of the company’s stock after purchasing an additional 275,105 shares during the quarter. Structure Therapeutics comprises about 8.2% of BVF Inc. IL’s portfolio, making the stock its 4th largest holding. BVF Inc. IL owned about 5.73% of Structure Therapeutics worth $241,966,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of GPCR. Morgan Stanley raised its position in shares of Structure Therapeutics by 261.4% in the 4th quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after purchasing an additional 1,510,093 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Structure Therapeutics by 477.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock worth $116,228,000 after buying an additional 1,381,745 shares during the last quarter. Avoro Capital Advisors LLC raised its position in Structure Therapeutics by 21.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock worth $455,939,000 after buying an additional 1,150,000 shares during the last quarter. Deutsche Bank AG purchased a new position in Structure Therapeutics during the 4th quarter worth approximately $58,503,000. Finally, Principal Financial Group Inc. raised its position in Structure Therapeutics by 63.1% during the 4th quarter. Principal Financial Group Inc. now owns 1,284,210 shares of the company’s stock worth $89,317,000 after buying an additional 496,726 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Price Performance

NASDAQ:GPCR opened at $45.00 on Thursday. The firm has a market cap of $3.20 billion, a price-to-earnings ratio of -51.72 and a beta of -1.35. The company has a 50 day moving average price of $43.09 and a 200-day moving average price of $57.53. Structure Therapeutics Inc. Sponsored ADR has a 1-year low of $15.80 and a 1-year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.04. On average, sell-side analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

GPCR has been the subject of a number of recent research reports. Citizens Jmp reduced their price target on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research report on Friday, February 27th. HC Wainwright reduced their price target on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Wolfe Research initiated coverage on shares of Structure Therapeutics in a research report on Thursday, March 26th. They set a “peer perform” rating for the company. BMO Capital Markets set a $145.00 price target on shares of Structure Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. Finally, Wall Street Zen lowered shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $106.75.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.